Study · Randomized controlled trial · 2018

10 results

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH

Lancet (London, England)16 Aug 2018Cited by 615 (Europe PMC)

PMID30122305DOI10.1016/s0140-6736(18)31773-2PepBankPUB-30122305

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·05 mg daily gave -6·0% weight loss at week 52 versus -2·3% with placebo, a significant difference.
In plain wordsIn adults with obesity, semaglutide at the lowest dose led to more weight loss than placebo after 52 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss at week 52, 0·05 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0·05 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−6%
semaglutide 0.05 mg
Source sentences
Summary
Estimated mean weight loss was -2·3% for the placebo group versus -6·0% (0·05 mg)
3 context sentences(design, population, supporting numbers)
Summary · context
All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055).
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230501
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·1 mg daily gave -8·6% weight loss at week 52, significantly more than placebo.
In plain wordsIn adults with obesity, semaglutide at 0·1 mg led to more weight loss than placebo after 52 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss at week 52, 0·1 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0·1 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−8.6%
semaglutide 0.1 mg
Source sentences
Summary
-8·6% (0·1 mg)
3 context sentences(design, population, supporting numbers)
Summary · context
All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055).
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230502
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·2 mg daily gave -11·6% weight loss at week 52, significantly more than placebo.
In plain wordsIn adults with obesity, semaglutide at 0·2 mg led to more weight loss than placebo after 52 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss at week 52, 0·2 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0·2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−11.6%
semaglutide 0.2 mg
Source sentences
Summary
-11·6% (0·2 mg)
3 context sentences(design, population, supporting numbers)
Summary · context
All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055).
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230503
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·3 mg daily gave -11·2% weight loss at week 52, significantly more than placebo.
In plain wordsIn adults with obesity, semaglutide at 0·3 mg led to more weight loss than placebo after 52 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss at week 52, 0·3 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0·3 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−11.2%
semaglutide 0.3 mg
Source sentences
Summary
-11·2% (0·3 mg)
3 context sentences(design, population, supporting numbers)
Summary · context
All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055).
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230504
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·4 mg daily gave -13·8% weight loss at week 52, significantly more than placebo.
In plain wordsIn adults with obesity, semaglutide at 0·4 mg led to more weight loss than placebo after 52 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage weight loss at week 52, 0·4 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0·4 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−13.8%
semaglutide 0.4 mg
Source sentences
Summary
-13·8% (0·4 mg)
3 context sentences(design, population, supporting numbers)
Summary · context
All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055).
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230505
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, 37-65% of those given semaglutide 0·1 mg or more daily lost 10% or more of body weight, versus 10% with placebo.
In plain wordsIn adults with obesity, more people lost 10% or more of body weight on semaglutide than on placebo.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 10% or more
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0·1 mg or more once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Proportion with weight loss of 10% or more
37 to 65%
semaglutide 0.1 mg or more
Source sentences
Summary
Estimated weight loss of 10% or more occurred in 10% of participants receiving placebo compared with 37-65% receiving 0·1 mg or more of semaglutide (p<0·0001 vs placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230506
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, semaglutide 0·2 mg or more daily gave significantly greater weight loss (-13·8% to -11·2%) than liraglutide (-7·8%).
In plain wordsIn adults with obesity, semaglutide at 0·2 mg or more led to more weight loss than liraglutide.
Peptide
Semaglutide
Outcome
DecreaseWeight loss versus liraglutide at week 52
Study
n: not reported in source
Comparator
Liraglutide 3·0 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
0·2 mg or more once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
Mean bodyweight reductions for 0·2 mg or more of semaglutide versus liraglutide were all significant (-13·8% to -11·2% vs -7·8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230507
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity and without diabetes, liraglutide 3·0 mg daily gave -7·8% weight loss, significantly less than semaglutide 0·2 mg or more.
In plain wordsIn adults with obesity, liraglutide led to weight loss, but less than semaglutide at 0·2 mg or more.
Peptide
Liraglutide
Outcome
DecreaseWeight loss with liraglutide 3·0 mg at week 52
Study
n: not reported in source
Comparator
Semaglutide 0·2 mg or more
Outcome group
Body weight · Metabolic and weight
Studied dose
3·0 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−7.8%
liraglutide 3.0 mg
Source sentences
Summary
Mean bodyweight reductions for 0·2 mg or more of semaglutide versus liraglutide were all significant (-13·8% to -11·2% vs -7·8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230508
09HumanRandomized controlled trialSafety outcome
In adults with obesity, all semaglutide doses were generally well tolerated, with no new safety concerns.
In plain wordsIn adults with obesity, all semaglutide doses were generally well tolerated, with no new safety concerns reported.
Peptide
Semaglutide
Outcome
Not applicableOverall tolerability and safety
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0·05 mg to 0·4 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
All semaglutide doses were generally well tolerated, with no new safety concerns.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230509
10HumanRandomized controlled trialSafety outcome
In adults with obesity, the most common semaglutide adverse events were dose-related gastrointestinal symptoms, mainly nausea.
In plain wordsIn adults with obesity, the most common side effects of semaglutide were stomach and gut symptoms, mainly nausea, that grew with dose.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0·05 mg to 0·4 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events were dose-related gastrointestinal symptoms, primarily nausea, as seen previously with GLP-1 receptor agonists.
2 context sentences(design, population, supporting numbers)
Summary · context
We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial.
Summary · context
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m² or more.
Report a problemFND-3012230510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 5 completed · 5 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial page ClinicalTrials.govUpdated 14 Apr 2023

CompletedPhase 3Results postedNCT03611582

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Novo Nordisk A/Sn = 6111 Aug 2018 to 28 Apr 2020

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 11 Nov 2021

CompletedPhase 3Results postedNCT03548935

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 1,9614 Jun 2018 to 5 Mar 2021

Metabolism and Nutrition Disorder · Overweight or Obesity

Trial page ClinicalTrials.govUpdated 19 Nov 2021

CompletedPhase 3Results postedNCT03548987

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 9024 Jun 2018 to 20 Mar 2020

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 19 Jan 2022

CompletedPhase 3Results postedNCT03552757

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 1,2104 Jun 2018 to 1 May 2020

Obesity · Overweight

Trial page ClinicalTrials.govUpdated 9 Nov 2021

CompletedPhase 2Results postedNCT02453711

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Novo Nordisk A/Sn = 9571 Oct 2015 to 12 Apr 2017

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 17 Apr 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.